Screener
Rigel Pharmaceuticals RIGL Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:05 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001034842-26-000032
| Line item | As of / March 31, 2026 | As of / December 31, 2025 ⁽¹⁾ |
|---|---|---|
| Loans payable, net, current portion | 29,865 | 29,812 |
| Other accrued liabilities | 9,674 | 11,466 |
| Lease liabilities, current portion | 636 | 614 |
| Total current liabilities | 89,492 | 99,237 |
| Long-term portion of lease liabilities | 228 | 395 |
| Long-term portion of loans payable, net | 14,991 | 22,482 |
| Total liabilities | 104,711 | 122,114 |
| Commitments |
Item 1. Financial Statements
FAQ
- What is Rigel Pharmaceuticals's total current liabilities?
- Rigel Pharmaceuticals (RIGL) reported total current liabilities of $89.49M in Q1 2026.
- How has Rigel Pharmaceuticals's total current liabilities changed year-over-year?
- Rigel Pharmaceuticals's total current liabilities increased by 34.3% year-over-year, from $66.63M to $89.49M.
- What is the long-term trend for Rigel Pharmaceuticals's total current liabilities?
- Over 5 years (2020 to 2025), Rigel Pharmaceuticals's total current liabilities has grown at a 19.4% compound annual growth rate (CAGR), from $40.84M to $99.24M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Rigel Pharmaceuticals's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude